LifeStance Health Group (NASDAQ:LFST) Given New $16.00 Price Target at BTIG Research

LifeStance Health Group (NASDAQ:LFST) had its price target boosted by investment analysts at BTIG Research from $15.00 to $16.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 50.09% from the company’s previous close.

Several other analysts also recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of LifeStance Health Group in a research report on Wednesday, May 27th. KeyCorp increased their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Canaccord Genuity Group raised their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.62.

LifeStance Health Group Stock Performance

LFST opened at $10.66 on Friday. LifeStance Health Group has a fifty-two week low of $3.81 and a fifty-two week high of $11.76. The firm has a market cap of $4.13 billion, a PE ratio of 177.67 and a beta of 1.14. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $9.88 and a 200-day simple moving average of $8.03.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. During the same quarter in the prior year, the firm earned ($0.01) EPS. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. As a group, equities analysts predict that LifeStance Health Group will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the sale, the director owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. The trade was a 20.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the completion of the sale, the director directly owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 7,612,394 shares of company stock worth $62,938,451 over the last three months. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors have recently modified their holdings of the company. Silversmith Partners I GP LLC acquired a new position in shares of LifeStance Health Group during the 4th quarter worth about $100,842,000. Vanguard Group Inc. raised its position in shares of LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after buying an additional 1,839,465 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in LifeStance Health Group by 27.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after acquiring an additional 1,790,694 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported second-quarter revenue of $435.4 million, up 26% year over year and above analysts’ $414.6 million estimate. Earnings were $0.06 per share versus the $0.03 consensus and a $0.01 loss in the prior-year quarter. LifeStance Health Group Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved sharply: net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volumes rose 19% to 2.6 million, supported by an 11% increase in the clinician base to 8,542. LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
• Positive Sentiment: Management raised 2026 revenue guidance to $1.685 billion-$1.725 billion, along with adjusted EBITDA guidance of $215 million-$235 million. Third-quarter revenue guidance of $420 million-$440 million also exceeds the roughly $417.7 million analyst consensus. LifeStance Swings to Q2 Profit and Raises 2026 Revenue Guidance
• Positive Sentiment: The board authorized up to $100 million in additional common-stock repurchases under a replacement program, while quarterly operating cash flow reached $99.9 million. LifeStance Reports 26% Q2 Revenue Growth and Raises Outlook
• Neutral Sentiment: The earnings call emphasized expansion into new geographies, broader clinical specialties, clinician growth, and measurable patient outcomes as longer-term growth drivers. LifeStance Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the strong results, LFST trades at a high earnings multiple, cash of $225.9 million remains below net long-term debt of $259.0 million, and reported insider transactions have been dominated by selling. These factors could limit further upside if growth or profitability slows.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.